Animal Or Plant Cell Patents (Class 424/93.7)
-
Patent number: 9173975Abstract: Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft.Type: GrantFiled: April 23, 2010Date of Patent: November 3, 2015Assignees: Ingeneron, Inc., Board of Regents, The University of Texas SystemInventors: Andrew M. Altman, Eckhard U. Alt, Michael E. Coleman
-
Patent number: 9175262Abstract: Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.Type: GrantFiled: November 29, 2010Date of Patent: November 3, 2015Assignee: Pluristerm Ltd.Inventor: Zami Aberman
-
Patent number: 9173940Abstract: The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers.Type: GrantFiled: April 29, 2014Date of Patent: November 3, 2015Assignee: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA)Inventor: Daniel Banov
-
Patent number: 9169461Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).Type: GrantFiled: November 2, 2006Date of Patent: October 27, 2015Assignee: Therakos, Inc.Inventors: David Peritt, Kim Campbell, Amy Krutsick
-
Patent number: 9169490Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: GrantFiled: October 5, 2012Date of Patent: October 27, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Rudolf Jaenisch, Konrad Hochedlinger
-
Patent number: 9161901Abstract: A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.Type: GrantFiled: February 23, 2009Date of Patent: October 20, 2015Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Arun Kumar, Shyam S. Mohapatra, Don F. Cameron
-
Patent number: 9161953Abstract: The disclosure provides methods for treating diabetes by promoting graft survival and improved graft function in a patient receiving an islet transplant by treating the patient with a GLP-1 receptor agonist compound prior to the islet transplant. The methods may also comprise treating the islets with a GLP-1 receptor agonist compound prior to transplanting them in a patient. The methods may eliminate the need for immunosuppressive therapy in islet transplants. Any GLP-1 receptor agonist compound know in the art can be used in the methods described herein.Type: GrantFiled: December 20, 2011Date of Patent: October 20, 2015Assignees: Amylin Pharmaceuticals, LLC, Eli Lilly And CompanyInventor: Kwame Osei
-
Patent number: 9156189Abstract: A system for producing microbeads includes a microfluidic device defining a supply channel and a shearing channel, a microbead precursor material disposed in the supply channel, a carrier fluid disposed in the shearing channel, and a pressure distribution system fluidly connected to each of the supply channel and the shearing channel to control at least relative pressures of the microbead precursor material and the carrier fluid. The supply channel includes a check valve adapted to be subjected to a bias pressure that is sufficient to close the check valve to flow of microbead precursor material when a supply pressure of the microbead precursor material is below a threshold pressure and is open to flow of the microbead precursor material when the supply pressure of the microbead precursor material is greater than the threshold pressure.Type: GrantFiled: October 3, 2011Date of Patent: October 13, 2015Assignee: The Johns Hopkins UniversityInventors: Tza-Huei Wang, Weijie Beh, Dara L. Kraitchman, Hsa-Quan Mao
-
Patent number: 9149508Abstract: Methods and compositions are disclosed for improving vaccination in a subject with preexistent antibodies to the antigenic component of the immunizing vaccine. By temporarily sequestering, disabling, and/or suppressing preexistent antibodies and/or Fc-mediated mechanisms according to the various example embodiments, the target antigenic component of a vaccine has an increased opportunity to enter antigen-presenting cells through the same pathway that it would use in seronegative subjects. A balanced immune environment is thereby restored and B cells are properly activated to produce antigen-specific antibodies following vaccination.Type: GrantFiled: October 25, 2012Date of Patent: October 6, 2015Assignee: Sigmovir Biosystems, Inc.Inventors: Marina S. Boukhvalova, Jorge C. G. Blanco
-
Patent number: 9144584Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.Type: GrantFiled: June 8, 2009Date of Patent: September 29, 2015Assignee: CELL4VET CORPORATIONInventors: Ching Shwun Lin, Tom F. Lue, Guiting Lin
-
Patent number: 9144382Abstract: A non-invasive method of producing a three-dimensional cardiac electrogram characteristic map for use in catheter ablation of ventricular tachycardia includes receiving left ventricle three-dimensional image data of a patient's heart; segmenting a left ventricle image of the patient's heart based on the left ventricle three-dimensional image data into scar tissue, normal myocardium tissue and left ventricle cavity regions; determining scar tissue thickness and normal myocardium tissue thickness for a plurality of portions of the left ventricle image of the patient's heart; receiving predetermined data that associate a value of at least one electrogram characteristic to each scar tissue thickness and each normal myocardium tissue thickness for the plurality of portions of said left ventricle image of said patient's heart; and generating the three-dimensional cardiac electrogram characteristic map of the at least one electrogram characteristic corresponding to the left ventricle image of the patient's heart basType: GrantFiled: April 9, 2012Date of Patent: September 29, 2015Assignee: The Johns Hopkins UniversityInventors: Saman Nazarian, Christopher Miller, Takeshi Sasaki
-
Patent number: 9145544Abstract: The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.Type: GrantFiled: January 21, 2015Date of Patent: September 29, 2015Assignee: Auxocell Laboratories, Inc.Inventors: Rouzbeh R. Taghizadeh, John Meade
-
Patent number: 9139811Abstract: The present invention relates to a composition for suppressing the death of stem cells during suspension culturing, a composition for mass culturing of stem cells, and a method for suppressing cell death of stem cells during suspension culturing. The composition of the present invention can be usefully used for effective single suspension culturing of stem cells, particularly, mesenchymal stem cells, or used for mass suspension culturing under the circumstances in which cell aggregation does not occur.Type: GrantFiled: December 27, 2011Date of Patent: September 22, 2015Assignee: SEOUL NATIONAL UNIVERSITY HOSPITALInventors: Eun Ju Lee, Hyo Soo Kim
-
Patent number: 9127252Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.Type: GrantFiled: March 13, 2013Date of Patent: September 8, 2015Assignee: The Brigham and Women's Hospital, Inc.Inventors: Keith D. Crawford, Christopher Southgate
-
Patent number: 9125906Abstract: Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.Type: GrantFiled: August 10, 2011Date of Patent: September 8, 2015Assignee: DePuy Synthes Products, Inc.Inventors: Charito S. Buensuceso, Anthony J. Kihm, Sridevi Dhanaraj, Roee Atlas, Israel Nur, Roberto Meidler, Liliana Bar
-
Patent number: 9125894Abstract: This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin.Type: GrantFiled: September 29, 2011Date of Patent: September 8, 2015Assignee: Massachusetts Eye & Ear InfirmaryInventor: Albert Edge
-
Patent number: 9127078Abstract: Methods and compositions for diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis are designed using newly identified epithelial cell-type specific splicing factors ESRP1 and ESRP2, which have roles in tumor suppression. Diagnostic reagents for the detection of these splicing factors in nucleotide or protein form are useful in such methods. Therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that change splicing events is described. RNCP1 is also identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing.Type: GrantFiled: July 21, 2009Date of Patent: September 8, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: Russ P. Carstens, Claude Warzecha, John Hogenesch, Trey Sato
-
Patent number: 9127255Abstract: The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types.Type: GrantFiled: June 14, 2011Date of Patent: September 8, 2015Assignee: Takara Bio Europe ABInventor: Janne Jensen
-
Patent number: 9121011Abstract: The present invention relates to: a method for producing an intermediate mesoderm cell from a human pluripotent stem cell, comprising a step of culturing the human pluripotent stem cell in a medium containing Activin A and Wnt or a functional equivalent of Wnt and a step of culturing cells in a medium containing BMP and Wnt or a functional equivalent of Wnt; to a method for producing a metanephric cell from the intermediate mesoderm cell produced by the first method; to a human pluripotent stem cell having a foreign reporter gene in the chromosome wherein the gene is expressed interlocked with the expression of endogenous OSR1; to a method for screening for an inducer for differentiation into intermediate mesoderm using the human pluripotent stem cell; and to a kit for inducing the differentiation into an intermediate mesoderm cell.Type: GrantFiled: July 21, 2011Date of Patent: September 1, 2015Assignee: KYOTO UNIVERSITYInventors: Kenji Osafune, Shin-ichi Mae, Masatoshi Kajiwara
-
Patent number: 9109245Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.Type: GrantFiled: February 6, 2013Date of Patent: August 18, 2015Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schultz
-
Patent number: 9097705Abstract: The present invention has successfully established a mixed culture system capable of actively proliferating a Kupffer cell in a primary culture of a cell population derived from a liver. Additionally, the present invention has successfully established a novel production method for efficiently producing a large amount of highly purified Kupffer cells using this mixed culture system.Type: GrantFiled: October 8, 2010Date of Patent: August 4, 2015Assignee: NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCESInventors: Hiroshi Kitani, Takato Takenouchi, Noriko Yamanaka, Miyako Yoshioka
-
Patent number: 9084787Abstract: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: March 11, 2013Date of Patent: July 21, 2015Assignee: STEMNION, INC.Inventors: George L Sing, Diana L Clarke, Vivienne S Marshall
-
Patent number: 9074189Abstract: Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.Type: GrantFiled: June 2, 2006Date of Patent: July 7, 2015Assignee: Janssen Biotech, Inc.Inventor: Sanjay Mistry
-
Patent number: 9068181Abstract: Microfluidic devices and methods for the encapsulation of particles within liquid droplets are disclosed. The new methods and devices form 1-100 picoliter-size monodisperse droplets containing the particles, such as single cells, encapsulated in individual liquid droplets. The particles can be encapsulated in droplets of a fluid by passing a fluid containing the particles through a high aspect-ratio microchannel to order the particles in the fluid, followed by forming the fluid into droplets. The resulting fraction of the liquid droplets with a single particle (e.g., a cell) is higher than the corresponding fraction of single-particle liquid droplets predicted by Poisson statistics.Type: GrantFiled: May 26, 2009Date of Patent: June 30, 2015Assignee: The General Hospital CorporationInventors: Jon F. Edd, Mehmet Toner, Dino Dicarlo, Daniel Irimia
-
Patent number: 9062288Abstract: Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent.Type: GrantFiled: August 20, 2009Date of Patent: June 23, 2015Assignee: Regeneus LTDInventor: Graham Vesey
-
Patent number: 9051550Abstract: The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.Type: GrantFiled: April 9, 2010Date of Patent: June 9, 2015Assignee: Arizona Board of Regents, on Behalf of The University of ArizonaInventors: Jordan Lancaster, Steve Goldman
-
Patent number: 9051548Abstract: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.Type: GrantFiled: February 3, 2010Date of Patent: June 9, 2015Assignee: Children's Medical Center CorporationInventors: Leonard I. Zon, Pulin Li
-
Patent number: 9044431Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.Type: GrantFiled: May 13, 2011Date of Patent: June 2, 2015Assignees: University of South Florida, Medical College of Georgia, Cryo-Cell International, Inc.Inventors: Paul R. Sanberg, Cesario V. Borlongan, Julie Allickson
-
Patent number: 9045747Abstract: The present invention relates to an apparatus and a method for fabricating a microcapsule, more particularly to an apparatus and a method for fabricating a microcapsule, which enable to encapsulate uniform cell number in a microcapsule through cell distribution, improve cell viability in the microcapsule through fluid exchange, and ensure uniform microcapsule size. The apparatus for fabricating a microcapsule according to the present invention uses a plurality of microchannels which are spatially connected with one another and are designed such that fluid flows through them in a particular direction, and comprises a cell supply unit which supplies a fluid mixture of cells and a cell dropletizing material; and a droplet forming unit in which a dropletization inducing fluid supplied from one of the plurality of microchannels joins with the fluid mixture of the cells and the cell dropletizing material to form a droplet.Type: GrantFiled: May 21, 2008Date of Patent: June 2, 2015Assignee: Korea Institute of Science and TechnologyInventors: Choong Kim, Ji Yoon Kang, Tae Song Kim
-
Patent number: 9044427Abstract: The present invention provides compositions and methods for promoting rapid healing and/or regeneration of damaged tissue resulting from a wound comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of (E)-4-carboxystyryl-4-chlorobenzylsulfone, or a functional derivative thereof, and a pharmaceutically acceptable excipient.Type: GrantFiled: March 24, 2011Date of Patent: June 2, 2015Assignee: ONCONOVA THERAPEUTICS, INCInventors: Ramesh Kumar, Manoj Maniar
-
Patent number: 9044530Abstract: The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold.Type: GrantFiled: December 19, 2012Date of Patent: June 2, 2015Assignee: SOUTHWEST RESEARCH INSTITUTEInventors: Jian Ling, Ben Antebi, Xingguo Cheng, Jeffrey N. Harris
-
Publication number: 20150147299Abstract: This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from amniotic cells. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.Type: ApplicationFiled: May 30, 2013Publication date: May 28, 2015Applicant: Cornell UniversityInventors: Shahin Rafii, Sina Y. Rabbany, Michael Ginsberg
-
Publication number: 20150147397Abstract: This invention is directed to aragonite and calcite hydrogel biomatrices, optionally seeded with precursor cells and uses thereof in tissue engineering, regeneration and repair, including in inducing or enhancing bone formation, cartilage formation or a combination thereof in a subject, and kits related thereto.Type: ApplicationFiled: April 29, 2013Publication date: May 28, 2015Inventor: Nir Altschuler
-
Publication number: 20150147300Abstract: Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.Type: ApplicationFiled: November 26, 2014Publication date: May 28, 2015Inventors: Jennifer E. Woodell-May, Joel C. Higgins, William King
-
Publication number: 20150147301Abstract: The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion.Type: ApplicationFiled: January 7, 2015Publication date: May 28, 2015Inventors: Ruslan Semechkin, Dmitry Isaev
-
Patent number: 9040038Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: April 8, 2013Date of Patent: May 26, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 9040039Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: April 18, 2013Date of Patent: May 26, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Publication number: 20150139904Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.Type: ApplicationFiled: May 21, 2013Publication date: May 21, 2015Applicant: University of MiamiInventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
-
Publication number: 20150139963Abstract: Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.Type: ApplicationFiled: September 8, 2014Publication date: May 21, 2015Inventors: Benjamin DEKEL, Orit HARARI-STEINBERG
-
Publication number: 20150139962Abstract: The present disclosure describes a method and composition for enhancing the survival of hematopoietic stem cells, preferably CD34+ derived from human umbilical cord or peripheral blood, in hypoxic and serum-deprived conditions by cultivating the cells in medium containing lysophosphatidic acid, preferably further comprising a gel, namely a biomimetic gel. The method and composition may be used in medicine or cosmetic application, in particular, in treatment of cardiac tissue and/or cardiac diseases, and/or in the treatment of wound healing namely diabetic wound healing.Type: ApplicationFiled: April 24, 2013Publication date: May 21, 2015Applicant: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.Inventors: Lino Da Silva Ferreira, Isabel Maria Fidalgo Dos Santos Silva Carvalho
-
Publication number: 20150139960Abstract: An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided.Type: ApplicationFiled: November 20, 2013Publication date: May 21, 2015Inventors: David Tumey, Sandra Berriman
-
Publication number: 20150139965Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.Type: ApplicationFiled: November 18, 2014Publication date: May 21, 2015Inventors: Nick Giannoukakis, Massimo M. Trucco
-
Publication number: 20150139961Abstract: The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells.Type: ApplicationFiled: June 4, 2014Publication date: May 21, 2015Inventor: Linzhao Cheng
-
Publication number: 20150139964Abstract: A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.Type: ApplicationFiled: November 13, 2014Publication date: May 21, 2015Inventor: Douglas REES
-
Publication number: 20150140059Abstract: This invention relates, e.g., to a synthetic compound, Oxy149, having the structure (Formula I) or a bioactive or pharmaceutical composition comprising Oxy149 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. Oxy149 can be delivered either locally or systemically.Type: ApplicationFiled: March 15, 2013Publication date: May 21, 2015Inventors: Farhad Parhami, Michael Jung, Frank Stappenbeck, William Pierce, K. Grant Taylor, Kevyn E. Merten
-
Publication number: 20150140057Abstract: This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: ApplicationFiled: August 20, 2014Publication date: May 21, 2015Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Publication number: 20150143558Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.Type: ApplicationFiled: November 10, 2014Publication date: May 21, 2015Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
-
Publication number: 20150140096Abstract: Particulate bone and structural bone, more specifically decalcified bone from endosteum having osteoinductive capacity and methods for their isolation and production are provided, more specifically, decalcified bone preparations derived from endosteal layer of bone are provided. Compositions formulated with material from endosteal layer of bone are provided along with preparation and methods of using decalcified endosteal compositions are disclosed. Endosteum is avascular and areolar in distinction to bone marrow which fills the canal. Because of its structure and anatomic position, endosteum is difficult to isolate and recognize, and therefore not regarded as an important constituent of allograft materials. One embodiment of the present invention allows for recognition and isolation of endosteum.Type: ApplicationFiled: March 12, 2014Publication date: May 21, 2015Applicant: VIVEX BIOMEDICAL INC.Inventor: Theodore I. Malinin
-
Publication number: 20150140058Abstract: A holey substrate now is used for constructing a graft product, such as building an auto-graft by 3D printing of living cells. When the autograft built atop the holey substrate is implanted, blood vessels and other patient tissues can grow through the holes.Type: ApplicationFiled: July 15, 2014Publication date: May 21, 2015Inventors: David Tumey, Sandra Berriman
-
Publication number: 20150139952Abstract: The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.Type: ApplicationFiled: August 11, 2014Publication date: May 21, 2015Inventor: Keith A. Webster